Pharmacokinetics of erythromycin on repetitive dosing. 1977

W A Colburn, and A R Di Santo, and M Gibaldi

Serum erythromycin concentration data from several repetitive dosing studies were analyzed with newly developed computer methods for fitting multiple-dose data and generating nonlinear least-squares estimates of pharmacokinetic parameters. This analysis indicates that the pharmacokinetics of erythromycin can be described by a one-compartment linear model with the following characteristics: (a) a lag time between the time of drug administration and the onset of absorption; (b) apparent zero-order rather than first-order absorption; (c) dose-to-dose variability in the rate and extent of absorption; and (d) day-to-day variability in the kinetics of elimination. The bioavailability of the third dose of erythromycin on a given day is considerably lower than that of the second dose or of the fourth and last dose of the day. The average apparent half-life of erythromycin was 1.8 hour on day 1 and 2.6 hours on day 3 of the repetitive dosing regimen.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W A Colburn, and A R Di Santo, and M Gibaldi
January 1999, Cancer chemotherapy and pharmacology,
W A Colburn, and A R Di Santo, and M Gibaldi
March 1975, Computer programs in biomedicine,
W A Colburn, and A R Di Santo, and M Gibaldi
January 1983, European journal of clinical pharmacology,
W A Colburn, and A R Di Santo, and M Gibaldi
February 1986, Journal of clinical pharmacology,
W A Colburn, and A R Di Santo, and M Gibaldi
May 1983, The Journal of antimicrobial chemotherapy,
W A Colburn, and A R Di Santo, and M Gibaldi
July 1987, Transplantation,
W A Colburn, and A R Di Santo, and M Gibaldi
January 1990, Therapeutic drug monitoring,
W A Colburn, and A R Di Santo, and M Gibaldi
August 1978, Journal of pharmaceutical sciences,
W A Colburn, and A R Di Santo, and M Gibaldi
January 1980, The Journal of international medical research,
W A Colburn, and A R Di Santo, and M Gibaldi
March 2005, European journal of clinical pharmacology,
Copied contents to your clipboard!